According to our latest study on “Lung Cancer Therapy Market Forecast to 2030 –Global Analysis – Therapy Type, Indication, and End User,” the market is expected to grow from US$ 31,018.32 million in 2022 and is expected to reach US$ 80,493.84 million by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030. The report highlights the key factors driving the lung cancer therapy market growth and prominent players with their developments in the market.
Get Your Free Sample Copy Today | Click Here: https://www.theinsightpartners.com/sample/TIPRE00030093
The lung cancer therapy market size is expanding with the rising cases of lung cancer, and the increasing habit of smoking and tobacco consumption in countries such as the UK, Germany, the US, and India. ~48,000 people get diagnosed with lung cancer, and ~35,000 people die yearly because of the disease in the UK. Smoking is the most common cause of lung cancer, while other causes include passive smoking and exposure to certain gases and chemicals. Currently, every fourth man (~27.0%) and every fifth woman (~21%) in Germany smokes regularly. The current landscape for lung cancer therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Multiple lung cancer therapies are in various stages of clinical development; pharmaceutical giants are working to expand their pipeline, which is a major opportunity prevailing in the lung cancer therapy market.
The lung cancer therapy market, by vaccine type, is segmented into non-invasive and minimally invasive. Minimally Invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. In 2022, the non-invasive therapy segment held the largest market share by product. However, minimally invasive segment is expected to grow at the fastest rate in the coming years. Radiation therapy, chemotherapy, and targeted therapy are the major types of non-invasive therapy for lung cancer. Radiation lung cancer therapy uses high energy and powerful X-rays to eliminate the cancerous cells, control their growth, and stop their spread in the lung. Radiation therapy is used before and after surgeries to shrink the tumor before surgery and kill the persistent cancer cells after the surgery. In chemotherapy, drugs are used to kill the new or existing cancerous cells in the lungs. Chemotherapy is considered an important treatment for lung cancer. According to the article “Chemotherapy Statistics,” in 2023, approximately 2% of stage 1 and 2 patients, 9% of stage 3 patients, and 27% of stage 4 patients receive chemotherapy for treatment of their lung cancer, respectively. The use of chemotherapy and radiation therapy for lung cancer is fueling the segment growth.
The lung cancer therapy market, by the indication, is segmented into non-small cell lung cancer and small cell lung cancer. In 2022, the non-small cell lung cancer segment held the largest market share by indication. Moreover, the non-small cell lung cancer segment is expected to grow at the fastest rate during the coming years. Non-small cell lung cancer (NSCLC) occurs when abnormal cells proliferate in the lung tissues. There are three primary forms of NSCLC cancer—adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Other types of NSCLC include adenosquamous carcinoma and sarcomatoid carcinoma, which are substantially less frequent in occurrence. NSCLC develops more slowly than small-cell lung cancer. It usually spreads to other parts of the patient’s body by the time it is diagnosed. Therefore, early diagnosis and treatment are crucial. According to the National Foundation for Cancer Research, NSCLC accounts for approximately 9 out of every 10 diagnoses. As per the same source, large-cell undifferentiated carcinoma lung cancer reports for ~10–15% of all NSCLC diagnoses. This type of lung cancer can originate in any part of the lung and is also known to grow and spread quickly.
Medtronic PLC, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Meiji Seika Pharma Co Ltd, Advanz Pharma Corp, and Olympus Corp are among the leading companies operating in the global lung cancer therapy market.
Companies operating in the lung cancer therapy market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the lung cancer therapy market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall lung cancer therapy market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
A few of the significant developments by key market players are listed below.
• In October 2023, Johnson & Johnson submitted the Type II extension of indication application seeking approval of the European Medicines Agency (EMA) for the use of RYBREVANT (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed) as the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
• In December 2022, RF Medical Co Ltd announced that the FDA approved their patented MYGEN M-3004 generator and MYOBLATE radiofrequency ablation system for commercialization in the US. These devices are used to treat damaged tumors and tissues.
• May 2021, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The drug is indicated among patients showing disease progression on or after platinum-based chemotherapy. RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation.
About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Lung Cancer Therapy, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.
Contact US
Contact Person : Ankit Mathur
Phone : +1-646-491-9876
E-mail : [email protected]
About Author
